Spark Therapeutics, Inc. (ONCE) Insider Sells $479,700.00 in Stock

Spark Therapeutics, Inc. (NASDAQ:ONCE) insider Daniel Faga sold 6,000 shares of the business’s stock in a transaction on Friday, October 20th. The shares were sold at an average price of $79.95, for a total transaction of $479,700.00. Following the sale, the insider now owns 6,000 shares in the company, valued at approximately $479,700. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Daniel Faga also recently made the following trade(s):

  • On Tuesday, October 24th, Daniel Faga sold 7,500 shares of Spark Therapeutics stock. The shares were sold at an average price of $80.96, for a total transaction of $607,200.00.
  • On Tuesday, September 19th, Daniel Faga sold 1,500 shares of Spark Therapeutics stock. The shares were sold at an average price of $85.00, for a total transaction of $127,500.00.
  • On Tuesday, September 12th, Daniel Faga sold 6,000 shares of Spark Therapeutics stock. The shares were sold at an average price of $82.50, for a total transaction of $495,000.00.
  • On Thursday, September 7th, Daniel Faga sold 3,000 shares of Spark Therapeutics stock. The shares were sold at an average price of $85.02, for a total transaction of $255,060.00.

Spark Therapeutics, Inc. (NASDAQ ONCE) opened at 80.99 on Friday. The company’s market cap is $2.53 billion. The firm’s 50-day moving average is $85.24 and its 200 day moving average is $85.24. Spark Therapeutics, Inc. has a 1-year low of $35.07 and a 1-year high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing the consensus estimate of ($1.75) by ($0.14). The business had revenue of $1.48 million during the quarter, compared to analyst estimates of $1.33 million. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. Spark Therapeutics’s revenue was up 14.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.04) EPS. Analysts predict that Spark Therapeutics, Inc. will post ($7.59) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Spark Therapeutics, Inc. (ONCE) Insider Sells $479,700.00 in Stock” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2017/10/27/spark-therapeutics-inc-once-insider-sells-479700-00-in-stock.html.

A number of analysts have recently commented on ONCE shares. UBS AG restated a “buy” rating and set a $92.00 target price (up previously from $70.00) on shares of Spark Therapeutics in a report on Thursday, August 3rd. Jefferies Group LLC assumed coverage on shares of Spark Therapeutics in a research note on Monday, July 10th. They issued a “buy” rating and a $85.00 price target on the stock. Chardan Capital upgraded shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $60.00 to $100.00 in a research note on Wednesday, August 2nd. Cantor Fitzgerald set a $94.00 price target on shares of Spark Therapeutics and gave the stock a “buy” rating in a research note on Monday, July 17th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $92.00 price target (up previously from $77.00) on shares of Spark Therapeutics in a research note on Thursday, August 3rd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and eighteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $90.47.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. boosted its holdings in Spark Therapeutics by 11.6% in the second quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock worth $122,689,000 after acquiring an additional 213,520 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Spark Therapeutics by 5.3% in the second quarter. Vanguard Group Inc. now owns 1,924,463 shares of the biotechnology company’s stock worth $114,968,000 after acquiring an additional 96,803 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Spark Therapeutics by 3.8% in the second quarter. JPMorgan Chase & Co. now owns 1,607,972 shares of the biotechnology company’s stock worth $96,060,000 after acquiring an additional 58,879 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in Spark Therapeutics in the second quarter worth about $30,848,000. Finally, Janus Capital Management LLC boosted its holdings in Spark Therapeutics by 21.4% in the first quarter. Janus Capital Management LLC now owns 458,743 shares of the biotechnology company’s stock worth $24,468,000 after acquiring an additional 80,750 shares in the last quarter. 77.29% of the stock is owned by institutional investors and hedge funds.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Insider Buying and Selling by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply